Flunarizine is a piperazine derivative medication classified as a calcium channel blocker used primarily for migraine prophylaxis. It functions by inhibiting the voltage-gated l-type calcium channels in neurons and peripheral vessels. This blockade reduces neuronal excitability and limits the cortical spreading depression that underlies migraine attacks. The same action leads to relaxation of cranial vasomotor muscles and improves blood flow regulation in the cerebral circulation. In addition to migraine prevention it is sometimes used off-label to treat vertigo and certain movement disorders. Its pharmacokinetic profile features high lipophilicity and extensive tissue binding that facilitate central nervous system penetration. The drug is metabolized slowly in the liver and eliminated mainly through hepatic pathways, resulting in a long half-life. Clinically, the sustained calcium channel inhibition produces a prophylactic effect that decreases migraine frequency over weeks of therapy.

Flunarizine is a long-acting benzodiazepine derivative used primarily to treat motion sickness and vertigo. Its therapeutic role involves reducing nausea and stabilizing vestibular function by modulating central neural pathways. Pharmacologically it blocks l-type calcium channels in neurons, decreasing excitatory neurotransmitter release. The resulting dampening of cortical overactivity leads to a lowered perception of motion-induced imbalance. Because the drug binds irreversibly to its target receptors, effects can persist for several days despite a single dose. This prolonged action supports its use in conditions requiring sustained vestibular suppression.

Flunarizine may cause drowsiness or fatigue in some patients. It can lead to weight gain due to increased appetite. Some users experience involuntary muscle movements or tremor. Mood changes such as depressive symptoms have been reported. Headache and nausea are among the less frequent side effects. Dry mouth or gastrointestinal discomfort can occur occasionally. Rarely, changes in blood pressure may be observed. Overall the drug is generally well tolerated but requires monitoring.

Flunarizine is associated with weight gain which occurs through increased appetite and reduced basal metabolism. It can cause drowsiness and sedation that may affect alertness during daily activities. Some patients experience dry mouth and mild gastrointestinal discomfort such as nausea or abdominal cramping. Occasionally it leads to extrapyramidal signs such as tremor or muscle stiffness. Visual disturbances including blurred vision and sensitivity to light have been reported. Headache and fatigue are also commonly observed during treatment. These effects are generally mild to moderate and tend to improve with continued use.